Pfizer China Congressional Delegate Seeks MRCT Approval Linkage
This article was originally published in PharmAsia News
In a new proposal submitted for consideration to China’s ongoing Congressional legislative sessions, a lone delegate from multinational drug makers has aggressively advocated legalizing approving new drugs using data obtained from multiregional clinical trials in which China takes part.
You may also be interested in...
The first data readout for remdesivir, the much anticipated antiviral for the coronavirus pandemic, is expected in days. Scrip surveys antiviral development and regulatory experts to gauge their interest and the key aspects to watch for in the milestone announcement.
China's centralized procurement scheme, if further expanded after causing the prices of 32 drugs to be cut by more than half in the latest round, will leave companies no room to breathe easy amid the already devastating coronavirus outbreak, analysts say.
As China is poised to supply medical products to fight the coronavirus around the world, a battle to banish its image of poor product quality is on.